A phase I dose escalation study of ad GV.EGR.TNF.11D (TNFeradeTMM Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation
T. Y. Seiwert*, T. Darg, D. Haraf, E. A. Blair, K. Stenson, E. E W Cohen, J. K. Salama, V. Villaflor, M. E. Witt, M. W. Lingen, R. R. Weichselbaum, E. E. Vokes
Dive into the research topics of 'A phase I dose escalation study of ad GV.EGR.TNF.11D (TNFeradeTMM Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation'. Together they form a unique fingerprint.